New generation dopaminergic agents. 6. Structure-activity relationship studies of a series of 4-(aminoethoxy)indole and 4-(aminoethoxy)indolone derivatives based on the newly discovered 3-hydroxyphenoxyethylamine D2 template

Journal of Medicinal Chemistry

Volumn 42, Issue 11, 1999, Pages 2007-2020

  Mewshaw, Richard E ^a   Webb, Michael B ^a   Marquis, Karen L ^a   McGaughey, Georgia B ^b   Shi, Xiaojie ^a   Wasik, Theodore ^a   Scerni, Rosemary ^a   Brennan, Julie A ^a   Andree, Terrance H ^a  

^a PFIZER INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

4 (AMINOETHOXY)INDOLE; 4 (AMINOETHOXY)INDOLONE; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; DRUG BINDING; DRUG CONFORMATION; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; LOCOMOTION; MOLECULAR MODEL; MOUSE; NONHUMAN; PHARMACOPHORE; PSYCHOSIS; SOCIAL PSYCHOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; BINDING, COMPETITIVE; CORPUS STRIATUM; DOPAMINE AGONISTS; ETHYLAMINES; HIPPOCAMPUS; INDOLES; MICE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOTOR ACTIVITY; RADIOLIGAND ASSAY; RATS; RECEPTORS, DOPAMINE D2; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033519655     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm990023s     Document Type: Article

References (38)

1. (a) Matthysse, S. Dopamine and the Pharmacology of Schizophrenia: the State of the Evidence. J. Psychiatr. Res. 1974, 11, 107-113.
2. (b) Meltzer, H. Y.; Stahl, S. M. The Dopamine Hypothesis of Schizophrenia: A Review. Schizophr. Bull. 1976, 2, 19-76.
3. (c) Seeman, P. Dopamine Receptors and the Dopamine Hypothesis of Schizophrenia. Synapse 1987, 1, 133-152.
4. (a) Roth, R. Dopamine Autoreceptors: Pharmacology, Function and Comparison with Postsynaptic Dopamine Receptors. Commun. Psychopharmacol. 1979, 3, 429-445.
5. (b) Clark, D.; Hijorth, S.; Carlsson, A. Dopamine Receptor Agonists: Mechanisms Underlying Autoreceptor Selectivity. II. Theoretical Considerations. J. Neural Transm. 1985, 62, 171-207.
6. (c) Carlsson, A. Dopamine Receptor Agonists: Intrinsic Activity vs State of Receptor. J. Neural. Transm. 1983, 57, 309-315.
7. (d) Meller, E.; Bohmaker, K.; Namba, Y.; Fiedhoff, A. J.; Goldstein, M. Relationship Between Receptor Occupancy and Response at Striatal Dopamine Autoreceptors. Mol. Pharmacol. 1987, 31, 592-598.
8. 2 Agonist Pharmacophore. Structure-activity Relationships of a Series of 2-(Aminomethyl)Chromans. J. Med. Chem. 1997, 40, 4235-4256.
9. 1-Phenylpiperazine Dopaminergic Templates. Bioorg. Med. Chem. Lett., 1998, 8, 295-300.
10. 2 Pharmacophore Via the 7-Hydroxy-2-Aminomethyl Benzoxazine Moiety. Med. Chem. Res. 1997, 7:8, 429-435.
11. (a) Kaiser, C.; Jain, T. Dopamine Receptors: Functions, Subtypes and Emerging Concepts. Med. Res. Rev. 1985, 5, 145-229.
12. (b) Wise, L. D.; Jaen, J. C. Design of Orally Active Dopamine Autoreceptor Agonists. In Drug Design in Neuroscience; Kozikowski, A. P., Ed.; Raven Press: New York, 1993; 119-148.
13. Mewshaw, R. E.; Marquis, K. L.; Shi, X.; McGaughey, G.; Stack, G.; Webb, M. B.; Abou-Gharbia, M.; Wasik, T.; Scerni, R.; Spangler, T.; Brennan, J. A.; Mazandarani, H.; Coupet, J.; Andree, T. H. New Generation Dopaminergic Agents. 4. Exploiting the 2-Methyl Chroman Scaffold. Synthesis and Evaluation of Two Novel Series of 2-(Aminomethyl)-3,4,7,9-tetrahydro-2H-pyrano[2,3-e]indole and Indol-8-one Derivatives. Tetrahedron 1998, 54, 7081-7108.
14. 2 Partial Agonists. Presented at the 1998 Charleston Conference, March 9-11, 1998, Isle of Palms, SC.
15. Stack, G. P.; Marquis, K. L.; Scherer, N. T.; Kang, Y. H.; Spangler, T. B.; Scerni, R. A.; Gardner, T. D.; Shropshire, A. T.; Kucharik, R. F.; Piesla, M. J.; Abou-Gharbia, M.; Andree, T. H. WAY-124486: Characterization of a Series of Aminomethylbenzodioxans as Dopamine Autoreceptor Agonists. Presented at the Society for Neurosciences Meeting in New Orleans, November 1992; Soc. Neurosci. Abst. 1992, 18, 378.
16. Stack, G. P.; Marquis, K. L.; Scherer, N. T.; Kang, Y. H.; Spangler, T. B.; Scerni, R. A.; Gardner, T. D.; Shropshire, A. T.; Kucharik, R. F.; Piesla, M. J.; Abou-Gharbia, M.; Andree, T. H. WAY-124486: Characterization of a Series of Aminomethylbenzodioxans as Dopamine Autoreceptor Agonists. Presented at the Society for Neurosciences Meeting in New Orleans, November 1992; Soc. Neurosci. Abst. 1992, 18, 378.
17. Mitsunobu, O. The Use of Diethyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products. Synthesis 1981, 1-28.
18. Bartoli, G.; Palmieri, G. The Reaction of Vinyl Grignard Reagents with 2-Substituted Nitroarenes: A New Approach to the Synthesis of 7-Substituted Indoles. Tetrahedron Lett. 1989, 30, 2129-2132.
19. Gassman, P. G.; van Bergen, T. J.; Gilbert, D. P.; Cue, B. W., Jr. J. Am. Chem. Soc. 1974, 96, 5495.
20. 3H]-quinpirole. Eur. J. Pharmacol. 1991, 203, 105-109.
21. 2-Like Dopamine Receptors in Rat. Brain J. Pharmacol. Exp. Ther. 1992, 262, 929-935.
22. 50) of an Enzymatic Reaction. Biochem. Pharmacol. 1973, 22, 3099-3108.
23. 2 Guanine Nucleotide-Bindmg Protein-Coupled Receptor: Utilization of Receptor State Binding Affinities. Mol. Pharmacol. 1992, 42, 432-438.
24. 35S]GTPγS Binding. Presented at the Society for Neurosciences Meeting in Washington DC, November 1996; Soc. Neurosci. Abst. 1996, 22, 831.
25. 35S]GTPγS Binding. Presented at the Society for Neurosciences Meeting in Washington DC, November 1996; Soc. Neurosci. Abst. 1996, 22, 831.
26. (a) Anden, N. E.; Nilsson, H. L.; Ros, E.; Thornstrom, U. Effects of B-HT 920 and B-HT 933 on Dopamine and Noradrenaline Autoreceptors in the Rat Brain. Acta Pharmacol. Toxicol. 1983, 52, 51-56.
27. (b) Eriksson, E.; Svensson, K.; Clark, D. The Putative Dopamine Autoreceptor Agonist B-HT 920 decreases Nigral Dopamine Cell Firing Rate and Prolactin Release in Rat. Life Sci. 1985, 36, 1819-1827.
28. Coward, D. M.; Dixon, A. K.; Urwyler, S.; White, T. G.; Enz, A.; Karobath, M.; Shearman, G. Partial Dopamine Agonistic and Atypical Neuroleptic Properties of the Amino-Ergolines SDZ 208-911 and SDZ 208-912. J. Pharmacol. Exp. Ther. 1990, 252, 279-285.
29. Anden, N.-E.; Carlsson, A.; Haggendal, J. Adrenergic Mechanisms. Annu. Rev. Pharmacol. 1961, 9, 119-134.
30. Meller, E.; Bohmaker, K.; Nambe, Y.; Friedhoff, A. J.; Goldstein, M. Relationship between receptor occupancy and response at striatal dopamine autoreceptors. Mol. Pharmacol. 1987, 31, 592-598.
31. Piesla, M. J.; Muth, E. A.; Marquis, K. L. The effects of dopamine agonists and antagonists in mice pretreated with reserpine. Soc. Neurosci. Abstr. 1992, 18, 1533.
32. (a) Freeman, H. S.; McDermed, J. D. In Chemical Regulation of Biological Mechanisms; Crieghton, A. M., Turner, S., Eds.; Royal Society of Chemistry: London, 1982; pp 154-165.
33. (b) McDermed, J. D.; Freeman, H. S.; Ferris, R. M. Enantioselective Binding of (+) and (-) 2-Amino-6,7-Dihydroxy-1,2,3,4-Tetrahydronaphthalenes and Related Agonists to Dopamine Receptors. In Catacholamines: Basic and Clinical Frontiers; Usdin, E., Ed.; Pergamon Press: New York, 1979; Vol. 1, p 568.
34. 3H]8-Hydroxy-2-(Di-n-Propylamino)Tetralin Binding to Pre-and Postsynaptic 5-Hydroxytryptamine Sites in Various Regions of the Rat Brain. J. Neurochem. 1985, 44, 1685-1696,.
35. 3H]Prazasin Binding. Mol. Pharmacol. 1986, 29, 321.
36. Martin, G. E.; Bendesky, R. J. Mouse locomotor activity: An in vivo test for dopamine autoreceptor activation. J. Pharmacol. Exp. Ther. 1984, 229, 706-711.
37. Costall, B.; Naylor, R. J.; Nohria, V. Climbing behavior induced by apomorphine in mice: A potential model for the detection of neuroleptic activity. Eur. J. Pharmacol. 1978, 50, 39-50.
38. Puech, A. J.; Rioux, P.; Poncelet, M.; Brochet, D.; Chermat, R.; Simon, P. Pharmacological properties of new antipsychotic agents: use of animal models. Neuropharmacology 1981, 20, 1279-1284.